Hikma Takes Significant Minority Stake In India's Unimark To Boost Presence Across Global Markets
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Hikma Pharmaceuticals PLC announced it acquired a minority strategic stake in Unimark Remedies Ltd. - a fast-growing Indian intermediates and API manufacturing firm - for $33 million, which could help the Jordanian generics firm expand beyond its Middle East and North Africa (MENA) focus and ramp up capability for the U.S. market